;)
Adeno-associated virus (AAV) vectors are pivotal in gene therapy, yet their production faces significant challenges, including scalability, low recovery rates, and the need for effective separation of empty and full capsids. This study presents a comprehensive AAV8 production platform developed together with CDMO Matica Biotechnology, and addresses industry pain points through innovative upstream and downstream processes.
By leveraging scalable bioreactor systems up to the 50L Biostat STR® bioreactor, we meticulously optimized the upstream process. The downstream process incorporated advanced filtration and chromatography techniques to enhance virus recovery and purity.
The combination of data analytics and screening tools enabled us to optimize process parameters in small scale, and we effectively translated the results to the 50L scale. The established platform offers a flexible solution for high-yield AAV production demands.
Speaker :